v3.26.1
Schedule of condensed interim consolidated statements of net loss and comprehensive loss (Details) - CAD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
IfrsStatementLineItems [Line Items]    
Revenue $ 871,066 $ 2,209,079
Cost of sales 240,649 310,699
Gross profit (loss) 630,417 1,898,380
Selling expenses 117,319 149,517
Administrative expenses 1,800,649 1,297,220
Financial expenses 755,213 1,911,196
Research and development costs, net of $3,828 in tax credits for the three-month period ended March 31, 2026, ($26,209 for the three-month period ended March 31, 2025) 313,711 206,503
  2,986,892 3,564,436
Loss before other elements (2,356,475)  
Other elements:    
Gain (Loss) on debt settlement 189,901 (23,474)
  189,901  
Loss before income taxes (2,166,574) (1,689,530)
Income tax expense    
Income Tax
Net loss for the period (2,166,574) (1,689,530)
Other comprehensive income (loss)    
Foreign exchange difference on translation of foreign operations (291,997)  
Total comprehensive loss for the period $ (2,458,571) $ (1,797,270)
Net loss per share (Note 16)    
Basic and diluted loss per share $ (0.17) $ (8.05)
Weighted average number of outstanding common shares 13,079,666 209,777
Previously stated [member]    
IfrsStatementLineItems [Line Items]    
Revenue $ 871,066  
Cost of sales 240,649  
Gross profit (loss) 630,417  
Selling expenses 117,319  
Administrative expenses 1,800,649  
Financial expenses 621,779  
Research and development costs, net of $3,828 in tax credits for the three-month period ended March 31, 2026, ($26,209 for the three-month period ended March 31, 2025) 313,711  
  2,853,458  
Loss before other elements (2,223,041)  
Other elements:    
Gain (Loss) on debt settlement 189,901  
  189,901  
Loss before income taxes (2,033,140)  
Income tax expense    
Income Tax  
Net loss for the period (2,033,140)  
Other comprehensive income (loss)    
Foreign exchange difference on translation of foreign operations (290,637)  
Total comprehensive loss for the period $ (2,323,777)  
Net loss per share (Note 16)    
Basic and diluted loss per share $ (0.16)  
Weighted average number of outstanding common shares 13,079,666  
Adjustments [Member]    
IfrsStatementLineItems [Line Items]    
Revenue  
Cost of sales  
Gross profit (loss)  
Selling expenses  
Administrative expenses  
Financial expenses 133,434  
Research and development costs, net of $3,828 in tax credits for the three-month period ended March 31, 2026, ($26,209 for the three-month period ended March 31, 2025)  
  133,434  
Loss before other elements (133,434)  
Other elements:    
Gain (Loss) on debt settlement  
   
Loss before income taxes (133,434)  
Income tax expense    
Income Tax  
Net loss for the period (133,434)  
Other comprehensive income (loss)    
Foreign exchange difference on translation of foreign operations (1,360)  
Total comprehensive loss for the period $ (134,794)  
Net loss per share (Note 16)    
Basic and diluted loss per share $ (0.01)  
Weighted average number of outstanding common shares 13,079,666